Sanofi Enhances Neurology Pipeline with Vigil Neuroscience Deal
Sanofi Completes Acquisition of Vigil Neuroscience
Sanofi is thrilled to announce the successful completion of its acquisition of Vigil Neuroscience, Inc. This exciting development marks a significant milestone for Sanofi as it continues to strengthen its early-stage pipeline focusing on neurology. With the acquisition of Vigil, Sanofi gains access to VG-3927, a novel oral TREM2 agonist poised for evaluation in a phase 2 clinical study aimed at Alzheimer's disease.
Investment Background
Earlier, in June 2024, Sanofi took a strategic step by investing $40 million in Vigil. This investment not only reinforced their collaboration but also granted Sanofi the exclusive right of first negotiation for the potential development and commercialization of VG-3927.
Acquisition Terms
The terms of the acquisition reflect a fair valuation of Vigil, where Sanofi acquired all outstanding common shares at a rate of $8 per share, culminating in an equity valuation of approximately $470 million. Additionally, Vigil’s shareholders are set to receive a non-transferrable contingent value right (CVR) per share. This CVR entitles them to a deferred cash payment of $2, dependent on the successful commercial launch of VG-3927.
Impact on Sanofi
It’s essential to note that the acquisition does not include Vigil’s second clinical program, VGL101. Despite this acquisition, Sanofi does not anticipate any adverse effects on its financial forecasts for 2025. The company remains committed to enhancing its pipeline and addressing critical health in neurodegenerative diseases.
About Sanofi
Sanofi prides itself on being a research and development-driven biopharmaceutical company harnessing the power of AI. Our commitment is to enhance people’s lives globally through innovative medicines and vaccines. Driven by an understanding of the immune system, we persist in creating breakthroughs that serve millions, powered by our passion for scientific progress. Our work is propelled by a singular goal: to effect positive change in the healthcare landscape.
Company Listings
Sanofi is publicly listed on both EURONEXT: SAN and NASDAQ: SNY, reflecting its engagement with global markets and investors.
Contact Us for More Information
For further inquiries or media relations, please connect with:
Media Relations Contacts
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Investor Relations Contacts
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Felix Lauscher | +1 908 612 7239 | felix.lauscher@sanofi.com
Frequently Asked Questions
What is the significance of the Sanofi-Vigil acquisition?
The acquisition allows Sanofi to expand its neurology pipeline and invest in innovative Alzheimer’s treatment options.
How will VG-3927 be evaluated?
VG-3927 is set to enter a phase 2 clinical study focusing on its efficacy in Alzheimer’s disease patients.
What valuation was placed on the Vigil Neuroscience acquisition?
Sanofi acquired Vigil at $8 per share, resulting in an approximate equity value of $470 million.
Who can I contact for media inquiries regarding Sanofi?
Media inquiries can be directed to Sandrine Guendoul at sandrine.guendoul@sanofi.com or other media contacts listed above.
What is Sanofi's approach to research and development?
Sanofi emphasizes an R&D-driven approach, focusing on innovative therapies that improve health outcomes globally.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.